Literature DB >> 17937578

Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes.

Gillian L McNab1, Ali Ahmad, Dippica Mistry, Robert A Stockley.   

Abstract

Small DNA fragments (SDFs) including normal M and alpha(1)-antitrypsin deficiency (alpha(1)-ATD) Z sequences were generated and transfected into peripheral blood monocytes from M subjects and Z alpha(1)-ATD patients. Untreated M and alpha(1)-ATD monocytes secreted 32 +/- 1.1 and 23 +/- 1.4 ng of alpha(1)-AT per 10(6) monocytes over 24 hr. After tumor necrosis factor (TNF)-alpha stimulation, the alpha(1)-AT secretion from M monocytes increased significantly to 50 +/- 2.1 ng/10(6) over 24 hr (p = 0.0004), whereas there was no change in secreted alpha(1)-AT from TNF-alpha-stimulated alpha(1)-ATD monocytes. However, after Z SDF transfection, M monocytes failed to increase alpha (1)-AT secretion in response to TNF-alpha stimulation. Transfecting alpha (1)-ATD monocytes with the M SDF resulted in a significant increase in alpha(1)-AT secretion (p = 0.03) after TNF-alpha stimulation to 55 +/- 2.7 ng/10(6) cells. Monocytes from a further 13 alpha(1)-ATD patients constitutively produced alpha(1)-AT after the first 24 hr. Transfection with either transfection reagent alone or with Z SDF slightly increased alpha (1)-AT secretion over the subsequent 24 hr. However, M SDF transfection significantly increased alpha(1)-AT secretion further, compared with untreated or sham transfection. Untreated, transfection reagent-treated, and Z SDF-transfected alpha(1)-ATD monocytes generated polymerase chain reaction products from Z primers. M SDF-treated alpha(1)-ATD monocytes generated bands with M primers, indicating the generation of a corrected transcript. In conclusion, the defective gene can be corrected in alpha(1)-ATD monocytes with SDFs, and treatment is associated with an increase in alpha(1)-AT secretion. The development of this methodology to repair the gene defect in hepatocytes should have beneficial effects on secretion, thereby protecting both the lung and liver.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937578     DOI: 10.1089/hum.2007.073

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

1.  A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency.

Authors:  Gillian L McNab; Timothy R Dafforn; Alice Wood; Elizabeth Sapey; Robert A Stockley
Journal:  Mamm Genome       Date:  2011-11-11       Impact factor: 2.957

2.  Sequence-specific correction of genomic hypoxanthine-guanine phosphoribosyl transferase mutations in lymphoblasts by small fragment homologous replacement.

Authors:  Babak Bedayat; Alireza Abdolmohamadi; Lin Ye; Rosalie Maurisse; Hooman Parsi; Jennifer Schwarz; Hamid Emamekhoo; Janice A Nicklas; J Patrick O'Neill; Dieter C Gruenert
Journal:  Oligonucleotides       Date:  2010-02

Review 3.  Oligo/polynucleotide-based gene modification: strategies and therapeutic potential.

Authors:  R Geoffrey Sargent; Soya Kim; Dieter C Gruenert
Journal:  Oligonucleotides       Date:  2011-03-21

4.  Nuclease-mediated double-strand break (DSB) enhancement of small fragment homologous recombination (SFHR) gene modification in human-induced pluripotent stem cells (hiPSCs).

Authors:  R Geoffrey Sargent; Shingo Suzuki; Dieter C Gruenert
Journal:  Methods Mol Biol       Date:  2014

5.  Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency.

Authors:  Caitriona McLean; Catherine M Greene; Noel G McElvaney
Journal:  Biologics       Date:  2009-07-13

Review 6.  Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.

Authors:  Laura Fregonese; Jan Stolk
Journal:  Orphanet J Rare Dis       Date:  2008-06-19       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.